TherapeuticsMD, Inc. (TXMD) News

TherapeuticsMD, Inc. (TXMD): $2.29

0.04 (+1.78%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add TXMD to Watchlist
Sign Up

Filter TXMD News Items

TXMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TXMD News From Around the Web

Below are the latest news stories about THERAPEUTICSMD INC that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

TherapeuticsMD Announces Third Quarter 2023 Financial Results

BOCA RATON, Fla., November 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 14, 2023

TherapeuticsMD Announces Second Quarter 2023 Financial Results

BOCA RATON, Fla., August 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.

Yahoo | August 14, 2023

TherapeuticsMD Announces First Quarter 2023 Financial Results

BOCA RATON, Fla., May 15, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.

Yahoo | May 15, 2023

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | April 14, 2023

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

BOCA RATON, Fla., April 07, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.

Yahoo | April 7, 2023

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

BOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products

Yahoo | January 3, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!